drugset / Trial / NCT00030615

Decitabine in Treating Patients With Advanced Solid Tumors

NCT00030615 ↗

Phase 1 Completed 24 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of decitabine in treating patients with advanced solid tumors that have not responded to previous treatment. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Timeline

Start
2001-12
Primary completion
2008-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule — Intravenous